Alzheimer’s disease expert Richard S. Isaacson, MD, explores strategies for care collaboration to optimize care for patients with Alzheimer’s disease (AD), the importance of determining patient-specific pharmacologic treatment approaches for patients with AD, and implementing approaches for effective communication with patients and caregivers surrounding AD diagnosis and management.
What role do biomarkers play in Alzheimer’s disease (AD)? The availability of a new pharmacologic class for AD offers the potential for disease modification when added early in the disease course, emphasizing the importance of novel biomarkers. In this podcast, experts review the association between biomarkers and symptoms of AD, the use of biomarkers for the early detection of AD, and the potential of available and emerging disease-modifying therapies for AD.